Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer (Q33379343)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18425418

retrieved

26 July 2017

title

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18425418

retrieved

26 July 2017

main subject

phase II clinical trial

0 references

lung cancer

1 reference

based on heuristic

inferred from title

author

Eric Van Cutsem

series ordinal

2

object named as

Eric Van Cutsem

0 references

Patrick Schöffski

series ordinal

7

object named as

Patrick Schöffski

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18425418

retrieved

26 July 2017

author name string

Johan Vansteenkiste

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18425418

retrieved

26 July 2017

Herlinde Dumez

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18425418

retrieved

26 July 2017

Cong Chen

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18425418

retrieved

26 July 2017

Justin L Ricker

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18425418

retrieved

26 July 2017

Sophia S Randolph

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18425418

retrieved

26 July 2017

publication date

19 April 2008

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18425418

retrieved

26 July 2017

published in

Investigational New Drugs

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18425418

retrieved

26 July 2017

volume

26

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18425418

retrieved

26 July 2017

issue

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18425418

retrieved

26 July 2017

page(s)

483-488

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18425418

retrieved

26 July 2017

cites work

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18425418

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18425418

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18425418

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18425418

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18425418

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18425418

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18425418

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18425418

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18425418

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18425418

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18425418

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18425418

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Histone deacetylase inhibitors: overview and perspectives

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18425418

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Histone deacetylase inhibitors in cancer therapy

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18425418

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Histone deacetylase inhibitors: molecular mechanisms of action

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18425418

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S10637-008-9131-6

1 reference

stated in

Fatcat

reference URL

https://api.fatcat.wiki/v0/release/kqnam7mjozgk3aujgd2wadayea

retrieved

30 July 2022

based on heuristic

mapped directly with Wikidata item

Dimensions Publication ID

1038891516

0 references

Fatcat ID

release_kqnam7mjozgk3aujgd2wadayea

1 reference

stated in

Fatcat

reference URL

https://api.fatcat.wiki/v0/release/kqnam7mjozgk3aujgd2wadayea

retrieved

30 July 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

18425418

1 reference

stated in

Fatcat

reference URL

https://api.fatcat.wiki/v0/release/kqnam7mjozgk3aujgd2wadayea

retrieved

30 July 2022

based on heuristic

mapped directly with Wikidata item

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33379343&oldid=2195303996"